<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">CPR</journal-id>
<journal-id journal-id-type="hwp">spcpr</journal-id>
<journal-id journal-id-type="nlm-ta">Eur J Cardiovasc Prev Rehabil</journal-id>
    <journal-title>European Journal of Preventive Cardiology</journal-title>
<issn pub-type="ppub">2047-4873</issn>
<issn pub-type="epub">2047-4881</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1741826711426090</article-id>
<article-id pub-id-type="publisher-id">10.1177_1741826711426090</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Smoking</subject>
<subj-group subj-group-type="heading">
<subject>Original scientific paper</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Smoking cessation and outcome in stable outpatients with coronary, cerebrovascular, or peripheral artery disease</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Álvarez</surname><given-names>Lorenzo Ramón</given-names></name>
<xref ref-type="aff" rid="aff1-1741826711426090">1</xref>
<xref ref-type="aff" rid="aff2-1741826711426090">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Balibrea</surname><given-names>José María</given-names></name>
<xref ref-type="aff" rid="aff3-1741826711426090">3</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Suriñach</surname><given-names>José María</given-names></name>
<xref ref-type="aff" rid="aff4-1741826711426090">4</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Coll</surname><given-names>Ramón</given-names></name>
<xref ref-type="aff" rid="aff3-1741826711426090">3</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Pascual</surname><given-names>María Teresa</given-names></name>
<xref ref-type="aff" rid="aff3-1741826711426090">3</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Toril</surname><given-names>Jesús</given-names></name>
<xref ref-type="aff" rid="aff5-1741826711426090">5</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>López-Jiménez</surname><given-names>Luciano</given-names></name>
<xref ref-type="aff" rid="aff6-1741826711426090">6</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Monreal</surname><given-names>Manuel</given-names></name>
<xref ref-type="aff" rid="aff3-1741826711426090">3</xref>
<xref ref-type="corresp" rid="corresp1-1741826711426090"/>
</contrib>
<contrib contrib-type="author">
<collab>the FRENA Investigators</collab>
</contrib>
</contrib-group>
<aff id="aff1-1741826711426090"><label>1</label>Hospital de Terrassa, Barcelona, Spain</aff>
<aff id="aff2-1741826711426090"><label>2</label>Universitat Autònoma de Barcelona (UAB) Spain</aff>
<aff id="aff3-1741826711426090"><label>3</label>Hospital Universitari Germans Trias I Pujol, Badalona, Spain</aff>
<aff id="aff4-1741826711426090"><label>4</label>Hospital Universitari Vall d’Hebrón, Barcelona, Spain</aff>
<aff id="aff5-1741826711426090"><label>5</label>Centro Médico y de Rehabilitación, Barcelona, Spain</aff>
<aff id="aff6-1741826711426090"><label>6</label>Hospital Provincial Reina Sofía, Córdoba, Spain</aff>
<author-notes>
<corresp id="corresp1-1741826711426090">Manuel Monreal, Servicio de Medicina Interna. Hospital Universitari Germans Trias i Pujol, 08916 Badalona, Spain Email: <email>mmonreal.germanstrias@gencat.cat</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>6</month>
<year>2013</year>
</pub-date>
<volume>20</volume>
<issue>3</issue>
<fpage>486</fpage>
<lpage>495</lpage>
<history>
<date date-type="received"><day>30</day><month>6</month><year>2011</year></date>
<date date-type="accepted"><day>19</day><month>9</month><year>2011</year></date>
</history>
<permissions>
<copyright-statement>© The European Society of Cardiology 2011 Reprints and permissions: sagepub.co.uk/journalsPermissions.nav</copyright-statement>
<copyright-year>2011</copyright-year>
<copyright-holder content-type="society">European Society of Cardiology</copyright-holder>
</permissions>
<abstract>
<sec id="sec12-1741826711426090"><title>Background:</title><p>The influence of smoking cessation on outcome in patients with peripheral arterial disease (PAD) has not been thoroughly studied.</p></sec>
<sec id="sec13-1741826711426090"><title>Methods:</title><p>FRENA is an ongoing registry of stable outpatients with symptomatic coronary artery disease (CAD), cerebrovascular disease (CVD), or PAD. We compared the mortality rate of those who quit vs. those who continued smoking.</p></sec>
<sec id="sec14-1741826711426090"><title>Results:</title><p>As of December 2010, 3523 patients were recruited, of whom 1182 (34%) were current smokers. Of these, 475 patients (40%) had CAD, 240 (20%) had CVD, and 467 (40%) had PAD. In all, 512 patients (43%) quit smoking. Over a mean follow-up of 14 months, 32 patients (2.7%) died and 95 (8.0%) had subsequent ischaemic events (myocardial infarction 32, ischaemic stroke 20, critical limb ischaemia/disabling claudication 53). In patients with CAD, the mortality rate was significantly lower in recent quitters (0.77 vs. 3.73 deaths per 100 patient-years; <italic>p</italic> = 0.013) than in persistent smokers. No quitter with CVD died (0.0 vs. 2.18 deaths; <italic>p</italic> = 0.092); but in patients with PAD there was a trend towards a higher mortality in quitters than in those who continued smoking (4.29 vs. 2.27 deaths; <italic>p</italic> = 0.357). On multivariate analysis, the relative risk for death in quitters was 0.20 (95% CI 0.05–0.75) in patients with CAD, 0.0 in those with CVD, and 1.83 (95% CI 0.65–5.15) in those with PAD.</p></sec>
<sec id="sec15-1741826711426090"><title>Conclusions:</title><p>Smoking cessation was associated with a significant decrease in mortality in patients with CAD, a non-significant decrease in those with CVD, and a non-significant increase in those with PAD.</p></sec>
</abstract>
<kwd-group>
<kwd>Arterial disease</kwd>
<kwd>mortality</kwd>
<kwd>secondary prevention</kwd>
<kwd>smoking</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="sec1-1741826711426090" sec-type="intro"><title>Introduction</title>
<p>Smoking cessation by apparently healthy people is associated with lower cardiovascular morbidity and mortality than in those who continue smoking.<sup><xref ref-type="bibr" rid="bibr1-1741826711426090">1</xref><xref ref-type="bibr" rid="bibr2-1741826711426090"/><xref ref-type="bibr" rid="bibr3-1741826711426090"/><xref ref-type="bibr" rid="bibr4-1741826711426090"/><xref ref-type="bibr" rid="bibr5-1741826711426090"/><xref ref-type="bibr" rid="bibr6-1741826711426090"/>–<xref ref-type="bibr" rid="bibr7-1741826711426090">7</xref></sup> A number of observational studies in patients with either coronary artery disease (CAD)<sup><xref ref-type="bibr" rid="bibr8-1741826711426090">8</xref><xref ref-type="bibr" rid="bibr9-1741826711426090"/><xref ref-type="bibr" rid="bibr10-1741826711426090"/><xref ref-type="bibr" rid="bibr11-1741826711426090"/><xref ref-type="bibr" rid="bibr12-1741826711426090"/><xref ref-type="bibr" rid="bibr13-1741826711426090"/>–<xref ref-type="bibr" rid="bibr14-1741826711426090">14</xref></sup> or cerebrovascular artery disease (CVD)<sup><xref ref-type="bibr" rid="bibr15-1741826711426090">15</xref>,<xref ref-type="bibr" rid="bibr16-1741826711426090">16</xref></sup> suggest that smoking cessation may also be associated with a lower mortality rate, but there is few available information on its influence on outcome in patients with peripheral artery disease (PAD). Consequently, guidelines in this area are based on experts’ consensus rather than on clinical evidence.<sup><xref ref-type="bibr" rid="bibr17-1741826711426090">17</xref><xref ref-type="bibr" rid="bibr18-1741826711426090"/><xref ref-type="bibr" rid="bibr19-1741826711426090"/>–<xref ref-type="bibr" rid="bibr20-1741826711426090">20</xref></sup></p>
<p>The FRENA (Factores de Riesgo y ENfermedad Arterial) Registry was initiated in March 2003 to prospectively record the current clinical management and outcome of stable outpatients with arterial disease in Spanish hospitals.<sup><xref ref-type="bibr" rid="bibr21-1741826711426090">21</xref>,<xref ref-type="bibr" rid="bibr22-1741826711426090">22</xref></sup> It is an ongoing, multicentre, observational registry of consecutive patients designed to gather and analyse data on treatment patterns and outcomes in patients with symptomatic ischaemic disease of the heart, brain, and/or major peripheral arteries. Data from this registry have been used to study the influence of body weight, glucose control, alcohol consumption, or concomitant use of proton-pump inhibitors and clopidogrel on outcome.<sup><xref ref-type="bibr" rid="bibr21-1741826711426090">21</xref><xref ref-type="bibr" rid="bibr22-1741826711426090"/><xref ref-type="bibr" rid="bibr23-1741826711426090"/><xref ref-type="bibr" rid="bibr24-1741826711426090"/>–<xref ref-type="bibr" rid="bibr25-1741826711426090">25</xref></sup> The aim of the current study was to compare the mortality rate and the incidence of subsequent ischaemic events in quitters vs. persistent smokers.</p>
</sec>
<sec id="sec2-1741826711426090" sec-type="methods"><title>Patients and methods</title>
<sec id="sec3-1741826711426090"><title>Inclusion criteria</title>
<p>Participating hospitals in the FRENA registry prospectively enrolled consecutive outpatients with symptomatic artery disease with at least one recent (&lt;3 months prior to enrolment) episode of CAD (manifesting as acute coronary syndrome), CVD (manifesting as ischaemic stroke), or PAD (either intermittent claudication with an ankle-brachial index &lt;0.9 or previous vascular intervention or limb amputation for PAD). The Fontaine classification was used for categorization of PAD.<sup><xref ref-type="bibr" rid="bibr26-1741826711426090">26</xref></sup> All patients provided oral consent to their participation in the registry, according to the requirements of the ethics committee within each hospital.</p>
</sec>
<sec id="sec4-1741826711426090"><title>Study design</title>
<p>At baseline, data on demographics, risk factors, comorbidities, and drug therapy were collected. At follow-up visits every 4 months, smoking was assessed with the question, ‘Is the patient currently smoking?’ Answer options were ‘yes’ and ‘no’. Currently smoking was defined as smoking at least one cigarette (or cigar or pipe) per day within the last month. Patients were categorized as never smokers, former smokers (ex-smokers who quit before entry in the FRENA Registry), recent quitters (those that reported not smoking at the first visit but who were current smokers at study entry), or persistent smokers (those who were smokers at study entry and reported smoking at any visit during follow- up). For the current study, only recent quitters and persistent smokers were considered. The primary outcome was all-cause mortality during follow-up. Secondary outcome was the incidence of subsequent ischaemic events (i.e. myocardial infarction, ischaemic stroke, or disabling claudication/ critical limb ischaemia).</p>
</sec>
<sec id="sec5-1741826711426090"><title>Definitions</title>
<p>Myocardial infarction was defined as a transient increase of creatine-kinase-MB or troponin in patients with ischaemic symptoms and/or typical electrocardiogram signs (development of pathologic Q-waves or ST-segment elevation or depression). Ischaemic stroke was diagnosed if the patient had an appropriate clinical event not resolving completely within 24 hours, and had a brain computed tomography or magnetic resonance imaging scan that showed a compatible low-density lesion. Disabling claudication/critical limb ischaemia was considered in patients with intermittent claudication when needing angioplasty, stenting, or surgery. In patients with Fontaine stages III or IV, critical limb ischaemia was considered when needing amputation. A patient was classified as having diabetes when there was a clinical history of diabetes or when they were taking insulin or oral antidiabetic agents. Patients were classified as having hypertension when there was a clinical history of hypertension or when they were taking antihypertensive medications. Creatinine clearance was calculated according to the Cockcroft and Gault formula.<sup><xref ref-type="bibr" rid="bibr27-1741826711426090">27</xref></sup></p>
</sec>
<sec id="sec6-1741826711426090"><title>Follow-up</title>
<p>A detailed history was performed on all patients at study entry (&lt;3 months after an acute ischaemic episode). Comorbid conditions were characterized, including a history of CAD, CVD, or PAD, diabetes mellitus, hypertension, hyperlipidaemia, chronic lung disease, chronic heart failure, cancer, smoking status, and alcohol consumption. Then, physical examination was performed comprising weight, height, heart rate, and blood pressure on standard conditions, after 5 min of rest. An electrocardiogram was also recorded. After the initial visit, patients were followed up at 4-month intervals for at least 12 months. At these visits, any change in medical history and data from physical examination were recorded, with special attention to risk factors, laboratory tests, lifestyle habits, the type, dose, and duration of treatment received, and clinical outcome. Physicians were allowed to use any and all appropriate medications, as dictated by their usual clinical practice patterns. They also provided to their patients a list of smoking cessation programmes and resources in their community and encouraged them to use stop medication aids.</p>
</sec>
<sec id="sec7-1741826711426090"><title>Data collection</title>
<p>The attending physicians ensured that eligible patients were consecutively enrolled. Data were recorded on to a computer-based case report form at each participating hospital and submitted to a centralized coordinating centre through a secure website. Patient identities remain confidential because they were identified by a unique number assigned by the study coordinating centre, which was responsible for all data management. Data quality was regularly monitored and documented electronically to detect inconsistencies or errors, which are resolved by the local coordinators. Data quality was also monitored by periodic visits to participating hospitals, by contract research organizations, who compared the medical records with the data in the web. A data audit was performed at periodic intervals.</p>
</sec>
<sec id="sec8-1741826711426090"><title>Statistical analysis</title>
<p>Categorical variables were compared using the chi-squared test (two-sided). Odds ratios and corresponding 95% confidence intervals were calculated, and a <italic>p</italic>-value &lt;0.05 was considered to be statistically significant. Incidence rates were calculated as cumulative incidence (events/100 patient-years) and compared using the rate ratio.<sup><xref ref-type="bibr" rid="bibr28-1741826711426090">28</xref></sup> The association between smoking status and mortality was assessed using a forward stepwise logistic regression analysis. Significance level of <italic>p </italic>&lt;<italic> </italic>0.10 was considered to include variables and <italic>p </italic>&gt;<italic> </italic>0.15 to exclude variables in the final multivariate model. We used Kaplan–Meier plots to estimate the association of smoking status with the risk to die. Statistical analyses were conducted with SPSS for Windows Release 17.0 (SPSS).</p>
</sec>
</sec>
<sec id="sec9-1741826711426090" sec-type="results"><title>Results</title>
<p>As of December 2010, 3523 patients were recruited in the FRENA registry, of whom 1182 (34%) were current smokers. Of these, 475 patients (40%) had CAD, 240 (20%) had CVD, and 467 (40%) had PAD. In all, 512 patients (43%) quit smoking and 670 continued smoking: 556 (83%) smoked cigarettes (10 ± 6.9 cigarettes/day), 43 (6.4%) smoked cigars (3.6 ± 4.5 cigars/day), and 57 all kinds of tobacco. Patients presenting with myocardial infarction more likely quit (60%), while those with intermittent claudication more likely continued smoking (75%), as shown in <xref ref-type="table" rid="table1-1741826711426090">Table 1</xref>. When overall considered, recent quitters were 2 years younger and less likely had chronic lung disease than persistent smokers. During follow-up, quitters had lower mean levels of systolic blood pressure and total cholesterol or high-density lipoprotein cholesterol, but had higher creatinine clearance levels than persistent smokers. In addition, quitters more likely received beta-blockers or angiotensin-converting enzyme inhibitors.
<table-wrap id="table1-1741826711426090" position="float"><label>Table 1.</label><caption><p>Clinical characteristics and therapeutic details of the 1182 patients, according to their current smoking habit</p></caption>
<graphic alternate-form-of="table1-1741826711426090" xlink:href="10.1177_1741826711426090-table1.tif"/>
<table frame="hsides"><thead align="left">
<tr><th>Quitters (<italic>n</italic> = 512)</th>
<th>Persistent smokers (<italic>n</italic> = 670)</th>
<th><italic>p</italic>-value</th>
</tr></thead>
<tbody align="left">
<tr>
<td colspan="4">Clinical characteristics</td>
</tr>
<tr>
<td> Age (years)</td>
<td>59 ± 11</td>
<td>61 ± 11</td>
<td>0.004</td>
</tr>
<tr>
<td> Gender (males)</td>
<td>467 (91)</td>
<td>614 (92)</td>
<td>NS</td>
</tr>
<tr>
<td> Body mass index (kg/m<sup>2</sup>)</td>
<td>28 ± 5</td>
<td>27 ± 4</td>
<td>NS</td>
</tr>
<tr>
<td colspan="4">Underlying diseases</td>
</tr>
<tr>
<td> Cancer</td>
<td>23 (4.5)</td>
<td>29 (4.3)</td>
<td>NS</td>
</tr>
<tr>
<td> Chronic lung disease</td>
<td>70 (14)</td>
<td>137 (21)</td>
<td>0.002</td>
</tr>
<tr>
<td> Chronic heart failure</td>
<td>12 (2.3)</td>
<td>14 (2.1)</td>
<td>NS</td>
</tr>
<tr>
<td> Hypertension</td>
<td>290 (57)</td>
<td>387 (58)</td>
<td>NS</td>
</tr>
<tr>
<td> Diabetes</td>
<td>363 (71)</td>
<td>439 (66)</td>
<td>0.069</td>
</tr>
<tr>
<td colspan="4">Clinical presentation</td>
</tr>
<tr>
<td> Angina</td>
<td>34 (6.6)</td>
<td>40 (6.0)</td>
<td>NS</td>
</tr>
<tr>
<td> Myocardial infarction</td>
<td>241 (47)</td>
<td>160 (24)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td> Ischaemic stroke</td>
<td>87 (17)</td>
<td>106 (16)</td>
<td>NS</td>
</tr>
<tr>
<td> Transient ischaemic attack</td>
<td>18 (3.5)</td>
<td>29 (4.3)</td>
<td>NS</td>
</tr>
<tr>
<td> Intermittent claudication</td>
<td>95 (19)</td>
<td>287 (43)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td> Ischaemic pain at rest</td>
<td>24 (4.7)</td>
<td>27 (4.0)</td>
<td>NS</td>
</tr>
<tr>
<td> Ischaemic skin lesions</td>
<td>13 (2.5)</td>
<td>21 (3.1)</td>
<td>NS</td>
</tr>
<tr>
<td colspan="4">Physical examination</td>
</tr>
<tr>
<td> Atrial fibrillation</td>
<td>11 (2.1)</td>
<td>12 (1.8)</td>
<td>NS</td>
</tr>
<tr>
<td> SBP (mmHg)</td>
<td>130 ± 17</td>
<td>136 ± 17</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td> DBP (mmHg)</td>
<td>75 ± 9</td>
<td>75 ± 10</td>
<td>NS</td>
</tr>
<tr>
<td colspan="4">Laboratory levels</td>
</tr>
<tr>
<td> CrCl (ml/min)</td>
<td>87 ± 29</td>
<td>83 ± 31</td>
<td>0.017</td>
</tr>
<tr>
<td> Total cholesterol (mg/dl)</td>
<td>179 ± 37</td>
<td>184 ± 38</td>
<td>0.025</td>
</tr>
<tr>
<td> HDL cholesterol (mg/dl)</td>
<td>59 ± 23</td>
<td>65 ± 27</td>
<td> &lt;0.001</td>
</tr>
<tr>
<td> LDL cholesterol (mg/dl)</td>
<td>108 ± 31</td>
<td>111 ± 35</td>
<td>NS</td>
</tr>
<tr>
<td> Glucose (mg/dl)</td>
<td>117 ± 34</td>
<td>117 ± 39</td>
<td>NS</td>
</tr>
<tr>
<td colspan="4">Drugs</td>
</tr>
<tr>
<td> Diuretics</td>
<td>128 (25)</td>
<td>180 (27)</td>
<td>NS</td>
</tr>
<tr>
<td> Beta-blockers</td>
<td>271 (53)</td>
<td>213 (32)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td> ACE inhibitors</td>
<td>253 (50)</td>
<td>293 (44)</td>
<td>0.057</td>
</tr>
<tr>
<td> Angiotensin-II antagonists</td>
<td>111 (22)</td>
<td>174 (26)</td>
<td>0.083</td>
</tr>
<tr>
<td> Calcium antagonists</td>
<td>95 (19)</td>
<td>130 (20)</td>
<td>NS</td>
</tr>
<tr>
<td> Antiplatelets</td>
<td>485 (95)</td>
<td>641 (96)</td>
<td>NS</td>
</tr>
<tr>
<td> Anticoagulants</td>
<td>54 (11)</td>
<td>40 (6.0)</td>
<td>0.004</td>
</tr>
<tr>
<td> Statins</td>
<td>430 (84)</td>
<td>541 (81)</td>
<td>NS</td>
</tr>
<tr>
<td> Insulin</td>
<td>45 (8.8)</td>
<td>76 (11)</td>
<td>NS</td>
</tr>
<tr>
<td> Oral antidiabetics</td>
<td>125 (25)</td>
<td>180 (27)</td>
<td>NS</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-1741826711426090"><p>Values are mean±standard deviation or <italic>n</italic> (%). ACE, angiotensin-converting enzyme; CrCl, creatinine clearance; DBP, diastolic blood pressure; HDL, high-density lipoprotein; LDL, low-density lipoprotein; NS, non-significant; SBP, systolic blood pressure.</p></fn></table-wrap-foot>
</table-wrap></p>
<p>Over a mean follow-up of 14 months (range 2–56 months), 32 patients (2.7%) died and 95 (8.0%) had subsequent ischaemic events (myocardial infarction 32, stroke 20, critical limb ischaemia/disabling claudication 53). In patients with CAD, the mortality rate was significantly lower in quitters (0.77 vs. 3.73 deaths per 100 patient-years; rate ratio: 0.21, 95% CI 0.05–0.73) than in persistent smokers (<xref ref-type="table" rid="table2-1741826711426090">Table 2</xref>). No quitter with CVD died, but in patients with PAD there was a trend towards more deaths among quitters (4.29 vs. 2.27 deaths; <italic>p</italic> = 0.357). In patients with CAD, the improved survival started beyond the sixth month (<xref ref-type="fig" rid="fig1-1741826711426090">Figure 1</xref>). In those with PAD, there were no differences at all (<xref ref-type="fig" rid="fig2-1741826711426090">Figure 2</xref>). Most deaths in patients with CAD (75%), but only 44% of deaths in those with PAD were due to cardiovascular reasons (<xref ref-type="table" rid="table3-1741826711426090">Table 3</xref>). As for the incidence of subsequent ischaemic events (myocardial infarction, ischaemic stroke, or critical limb ischaemia/disabling claudication), there were no differences between quitters and persistent smokers in any subgroup (<xref ref-type="table" rid="table2-1741826711426090">Table 2</xref>).
<fig id="fig1-1741826711426090" position="float"><label>Figure 1.</label><caption><p>Cumulative mortality during the first 3 years of follow-up for patients with coronary artery disease.</p></caption><graphic xlink:href="10.1177_1741826711426090-fig1.tif"/>
</fig>
<fig id="fig2-1741826711426090" position="float"><label>Figure 2.</label><caption><p>Cumulative mortality during the first 3 years of follow-up for patients with peripheral artery disease.</p></caption><graphic xlink:href="10.1177_1741826711426090-fig2.tif"/>
</fig>
<table-wrap id="table2-1741826711426090" position="float"><label>Table 2 .</label><caption><p>Clinical outcomes according to type of disease and smoking habit</p></caption>
<graphic alternate-form-of="table2-1741826711426090" xlink:href="10.1177_1741826711426090-table2.tif"/>
<table frame="hsides"><thead align="left">
<tr><th>Quitters</th>
<th>Persistent smokers</th>
<th>Rate ratio (95% CI)</th>
<th><italic>p</italic>-value</th>
</tr></thead>
<tbody align="left">
<tr>
<td>CAD patients (<italic>n</italic>)</td>
<td>275</td>
<td>200</td>
</tr>
<tr>
<td> Follow-up (years)</td>
<td>389</td>
<td>241</td>
</tr>
<tr>
<td> Myocardial infarction</td>
<td>2.32 (1.13–4.25)</td>
<td>3.32 (1.54–6.30)</td>
<td>0.70 (0.26–1.88)</td>
<td>NS</td>
</tr>
<tr>
<td> Acute ischaemic stroke</td>
<td>0.26 (0.13–1.27)</td>
<td>0</td>
<td>–</td>
<td>NS</td>
</tr>
<tr>
<td> Disabling claudication/CLI</td>
<td>0.26 (0.13–1.27)</td>
<td>0.41 (0.02–2.05)</td>
<td>0.62 (0.02–24.2)</td>
<td>NS</td>
</tr>
<tr>
<td> Any of the above</td>
<td>2.32 (1.13–4.25)</td>
<td>3.32 (1.54–6.30)</td>
<td>0.70 (0.26–1.88)</td>
<td>NS</td>
</tr>
<tr>
<td> Overall death</td>
<td>0.77 (0.20–2.10)</td>
<td>3.73 (1.82–6.85)</td>
<td>0.21 (0.05–0.73)</td>
<td>0.013</td>
</tr>
<tr>
<td>CVD patients (<italic>n</italic>)</td>
<td>105</td>
<td>135</td>
</tr>
<tr>
<td> Follow-up (years)</td>
<td>149</td>
<td>183</td>
</tr>
<tr>
<td> Myocardial infarction</td>
<td>1.34 (0.22–4.43)</td>
<td>1.09 (0.18–3.60)</td>
<td>1.23 (0.13–11.8)</td>
<td>NS</td>
</tr>
<tr>
<td> Acute ischaemic stroke</td>
<td>4.02 (1.63–8.37)</td>
<td>1.64 (0.42–4.45)</td>
<td>2.46 (0.61–12.0)</td>
<td>NS</td>
</tr>
<tr>
<td> Disabling claudication/CLI</td>
<td>0.67 (0.34–3.31)</td>
<td>1.10 (0.18–3.60)</td>
<td>0.61 (0.02–8.08)</td>
<td>NS</td>
</tr>
<tr>
<td> Any of the above</td>
<td>4.69 (2.05–9.28)</td>
<td>2.73 (1.00–6.04)</td>
<td>1.72 (0.53–5.93)</td>
<td>NS</td>
</tr>
<tr>
<td> Overall death</td>
<td>0</td>
<td>2.18 (0.69–5.26)</td>
<td>0.0 (0.0–1.37)</td>
<td>0.092</td>
</tr>
<tr>
<td>PAD patients (<italic>n</italic>)</td>
<td>132</td>
<td>335</td>
</tr>
<tr>
<td> Follow-up (years)</td>
<td>140</td>
<td>438</td>
</tr>
<tr>
<td> Myocardial infarction</td>
<td>2.86 (0.91–6.89)</td>
<td>1.60 (0.70–3.16)</td>
<td>1.79 (0.46–6.17)</td>
<td>NS</td>
</tr>
<tr>
<td> Acute ischaemic stroke</td>
<td>1.43 (0.24–4.72)</td>
<td>1.82 (0.84–3.45)</td>
<td>0.78 (0.11–3.38)</td>
<td>NS</td>
</tr>
<tr>
<td> Disabling claudication/CLI</td>
<td>9.29 (5.16–15.5)</td>
<td>7.95 (5.62–10.9)</td>
<td>1.16 (0.59–2.16)</td>
<td>NS</td>
</tr>
<tr>
<td> Any of the above</td>
<td>11.4 (6.76–18.2)</td>
<td>11.4 (8.52–14.8)</td>
<td>1.00 (0.55–1.73)</td>
<td>NS</td>
</tr>
<tr>
<td> Overall death</td>
<td>4.29 (1.74–8.91)</td>
<td>2.27 (1.15–4.05)</td>
<td>1.88 (0.63–5.18)</td>
<td>NS</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn2-1741826711426090"><p>Values are incidence per 100 patient-years (95% confidence interval). CAD, coronary artery disease; CLI, critical limb ischaemia; CVD, cerebrovascular disease; NS, non-significant; PAD, peripheral artery disease.</p></fn></table-wrap-foot>
</table-wrap>
<table-wrap id="table3-1741826711426090" position="float"><label>Table 3 .</label><caption><p>Causes of death according to disease and smoking habit</p></caption>
<graphic alternate-form-of="table3-1741826711426090" xlink:href="10.1177_1741826711426090-table3.tif"/>
<table frame="hsides"><thead align="left">
<tr><th rowspan="2"/><th colspan="2">Coronary artery disease</th>
<th colspan="2">Cerebrovascular disease</th>
<th colspan="2">Peripheral artery disease</th>
</tr>
<tr><th>Quitters (<italic>n</italic> = 275)</th>
<th>Smokers (<italic>n</italic> = 200)</th>
<th>Quitters (<italic>n</italic> = 105)</th>
<th>Smokers (<italic>n</italic> = 135)</th>
<th>Quitters (<italic>n</italic> = 132)</th>
<th>Smokers (<italic>n</italic> = 336)</th>
</tr></thead>
<tbody align="left">
<tr>
<td>Sudden death</td>
<td>1 (0.4)</td>
<td>4 (2.0)</td>
<td>0</td>
<td>0</td>
<td>1 (0.8)</td>
<td>1 (0.3)</td>
</tr>
<tr>
<td>Fatal critical limb ischaemia</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>2 (1.5)</td>
<td>2 (0.6)</td>
</tr>
<tr>
<td>Heart insufficiency</td>
<td>1 (0.4)</td>
<td>1 (0.5)</td>
<td>0</td>
<td>1 (0.7)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Fatal myocardial infarction</td>
<td>0</td>
<td>1 (0.5)</td>
<td>0</td>
<td>0</td>
<td>1 (0.8)</td>
<td>0</td>
</tr>
<tr>
<td>Fatal ischaemic stroke</td>
<td>0</td>
<td>1 (0.5)</td>
<td>0</td>
<td>1 (0.7)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Bleeding</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>1 (0.8)</td>
<td>2 (0.6)</td>
</tr>
<tr>
<td>Infection</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>1 (0.7)</td>
<td>0</td>
<td>2 (0.6)</td>
</tr>
<tr>
<td>Disseminated cancer</td>
<td>1 (0.4)</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>1 (0.8)</td>
<td>0</td>
</tr>
<tr>
<td>Chronic lung disease</td>
<td>0</td>
<td>1 (1.5)</td>
<td>0</td>
<td>1 (0.7)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Liver cirrhosis</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>1 (0.3)</td>
</tr>
<tr>
<td>Unknown</td>
<td>0</td>
<td>1 (1.5)</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>2 (0.6)</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn3-1741826711426090"><p>Values are <italic>n</italic> (%).</p></fn></table-wrap-foot>
</table-wrap></p>
<p>Patients who died were significantly older, more likely had chronic lung disease, diabetes, atrial fibrillation, or renal insufficiency, and more frequently received anticoagulants or insulin, but less likely received statins than those who survived (<xref ref-type="table" rid="table4-1741826711426090">Table 4</xref>). Among patients who continued smoking, there were no differences in the daily number of cigarettes between those who died and those who did not (7.1 ± 7.2 vs. 10 ± 6.9, respectively; <italic>p</italic> = 0.301). Multivariate analysis confirmed that quitters with CAD had a significantly lower mortality than persistent smokers (relative risk 0.20, 95% CI 0.05–0.75) and there was a trend towards a lower mortality in quitters with CVD (<xref ref-type="table" rid="table5-1741826711426090">Table 5</xref>). However, quitters with PAD had a trend towards a higher mortality. The relative risk was 1.70 (95% CI 0.51–5.68) in patients with Fontaine stage II, 1.47 (95% CI 0.49–4.35) in those with Fontaine stage III, and 2.31 (95% CI 0.21–25.6) in those with Fontaine stage IV.
<table-wrap id="table4-1741826711426090" position="float"><label>Table 4 .</label><caption><p>Risk factors for mortality: univariate analysis</p></caption>
<graphic alternate-form-of="table4-1741826711426090" xlink:href="10.1177_1741826711426090-table4.tif"/>
<table frame="hsides"><thead align="left">
<tr><th>Death (<italic>n</italic> = 32)</th>
<th>No death (<italic>n</italic> = 1150)</th>
<th><italic>p</italic>-value</th>
</tr></thead>
<tbody align="left">
<tr>
<td colspan="4">Clinical characteristics</td>
</tr>
<tr>
<td> Age &gt;60 years</td>
<td>25 (78)</td>
<td>569 (50)</td>
<td>0.002</td>
</tr>
<tr>
<td> Gender (males)</td>
<td>30 (94)</td>
<td>1051 (91)</td>
<td>NS</td>
</tr>
<tr>
<td> Body mass index &gt;27 kg/m<sup>2</sup></td>
<td>12 (41)</td>
<td>580 (52)</td>
<td>NS</td>
</tr>
<tr>
<td colspan="4">Underlying diseases</td>
</tr>
<tr>
<td> Cancer</td>
<td>5 (16)</td>
<td>47 (4.1)</td>
<td>0.011</td>
</tr>
<tr>
<td> Chronic lung disease</td>
<td>13 (41)</td>
<td>194 (17)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td> Chronic heart failure</td>
<td>1 (3.1)</td>
<td>25 (2.2)</td>
<td>NS</td>
</tr>
<tr>
<td> Hypertension</td>
<td>22 (69)</td>
<td>655 (57)</td>
<td>NS</td>
</tr>
<tr>
<td> Diabetes</td>
<td>16 (50)</td>
<td>360 (31)</td>
<td>0.018</td>
</tr>
<tr>
<td colspan="4">Smoking habit</td>
</tr>
<tr>
<td> Quitters</td>
<td>9 (28)</td>
<td>499 (44)</td>
<td>0.090</td>
</tr>
<tr>
<td colspan="4">Initial clinical presentation</td>
</tr>
<tr>
<td> Coronary artery disease</td>
<td>12 (38)</td>
<td>458 (40)</td>
<td>NS</td>
</tr>
<tr>
<td> Cerebrovascular disease</td>
<td>4 (13)</td>
<td>238 (21)</td>
<td>NS</td>
</tr>
<tr>
<td> Peripheral artery disease</td>
<td>16 (50)</td>
<td>451 (39)</td>
<td>NS</td>
</tr>
<tr>
<td colspan="4">Physical examination</td>
</tr>
<tr>
<td> Atrial fibrillation</td>
<td>3 (9.4)</td>
<td>20 (1.7)</td>
<td>0.002</td>
</tr>
<tr>
<td> Mean SBP &gt;140 mmHg</td>
<td>13 (41)</td>
<td>395 (34)</td>
<td>NS</td>
</tr>
<tr>
<td> Mean DBP &gt;90 mmHg</td>
<td>2 (6.3)</td>
<td>70 (6.1)</td>
<td>NS</td>
</tr>
<tr>
<td colspan="4">Mean laboratory levels</td>
</tr>
<tr>
<td> Creatinine clearance &lt;60 ml/min</td>
<td>18 (60)</td>
<td>208 (19)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td> Total cholesterol &gt;190 mg/dl</td>
<td>8 (28)</td>
<td>433 (39)</td>
<td>NS</td>
</tr>
<tr>
<td> LDL cholesterol &gt;100 mg/dl</td>
<td>14 (58)</td>
<td>644 (60)</td>
<td>NS</td>
</tr>
<tr>
<td> Glucose &gt;100 mg/dl</td>
<td>23 (79)</td>
<td>687 (61)</td>
<td>0.080</td>
</tr>
<tr>
<td colspan="4">Drugs</td>
</tr>
<tr>
<td> Diuretics</td>
<td>13 (41)</td>
<td>295 (26)</td>
<td>NS</td>
</tr>
<tr>
<td> Beta-blockers</td>
<td>12 (38)</td>
<td>472 (41)</td>
<td>NS</td>
</tr>
<tr>
<td> ACE inhibitors</td>
<td>14 (44)</td>
<td>532 (46)</td>
<td>NS</td>
</tr>
<tr>
<td> Angiotensin-II antagonists</td>
<td>7 (22)</td>
<td>278 (24)</td>
<td>NS</td>
</tr>
<tr>
<td> Calcium antagonists</td>
<td>7 (22)</td>
<td>218 (19)</td>
<td>NS</td>
</tr>
<tr>
<td> Antiplatelets</td>
<td>29 (91)</td>
<td>1097 (96)</td>
<td>NS</td>
</tr>
<tr>
<td> Anticoagulants</td>
<td>9 (28)</td>
<td>85 (7.4)</td>
<td>0.001</td>
</tr>
<tr>
<td> Statins</td>
<td>19 (59)</td>
<td>952 (83)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td> Insulin</td>
<td>7 (22)</td>
<td>114 (9.9)</td>
<td>0.015</td>
</tr>
<tr>
<td> Oral antidiabetics</td>
<td>6 (19)</td>
<td>299 (26)</td>
<td>NS</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn4-1741826711426090"><p>Values are <italic>n</italic> (%). ACE, angiotensin-converting enzyme; DBP, diastolic blood pressure; LDL, low-density lipoprotein; SBP, systolic blood pressure.</p></fn></table-wrap-foot>
</table-wrap>
<table-wrap id="table5-1741826711426090" position="float"><label>Table 5 .</label><caption><p>Risk factors for mortality: multivariate analysis</p></caption>
<graphic alternate-form-of="table5-1741826711426090" xlink:href="10.1177_1741826711426090-table5.tif"/>
<table frame="hsides"><thead align="left">
<tr><th>All patients</th>
<th>Coronary artery disease</th>
<th>Cerebrovascular disease</th>
<th>Peripheral artery disease</th>
</tr></thead>
<tbody align="left">
<tr>
<td colspan="5">Underlying diseases</td>
</tr>
<tr>
<td> Cancer</td>
<td>3.59 (1.34–9.64)</td>
<td>4.98 (0.62–40.3)</td>
<td>–</td>
<td>2.59 (0.75–8.91)</td>
</tr>
<tr>
<td> Diabetes</td>
<td>5.42 (2.33–12.6)</td>
<td>–</td>
<td>–</td>
<td>3.24 (1.12–9.37)</td>
</tr>
<tr>
<td colspan="5">Smoking habit</td>
</tr>
<tr>
<td> Quitters</td>
<td>0.51 (0.22–1.15)</td>
<td>0.20 (0.05–0.75)</td>
<td>0</td>
<td>1.83 (0.65–5.15)</td>
</tr>
<tr>
<td colspan="5">Physical examination</td>
</tr>
<tr>
<td> Atrial fibrillation</td>
<td>6.78 (1.89–24.3)</td>
<td>10.0 (1.19–84.6)</td>
<td>–</td>
<td>22.2 (4.27–116)</td>
</tr>
<tr>
<td colspan="5">Mean serum levels</td>
</tr>
<tr>
<td>CrCl &lt;60 ml/min</td>
<td>4.43 (2.09–9.40)</td>
<td>–</td>
<td>–</td>
<td>13.8 (3.74–51.2)</td>
</tr>
<tr>
<td colspan="5">Drugs,</td>
</tr>
<tr>
<td> Anticoagulants</td>
<td>–</td>
<td>–</td>
<td>16.6 (1.71–161)</td>
<td>–</td>
</tr>
<tr>
<td> Insulin</td>
<td>–</td>
<td>2.77 (0.58–13.1)</td>
<td>–</td>
<td>–</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn5-1741826711426090"><p>Values are relative risk (95% confidence interval). CrCl, creatinine clearance.</p></fn></table-wrap-foot>
</table-wrap></p>
</sec>
<sec id="sec10-1741826711426090" sec-type="discussion"><title>Discussion</title>
<p>A number of observational studies consistently found that smoking cessation rapidly decreases the incidence of subsequent myocardial infarction and stroke and the mortality rate in patients with CAD or CVD.<sup><xref ref-type="bibr" rid="bibr8-1741826711426090">8</xref><xref ref-type="bibr" rid="bibr9-1741826711426090"/><xref ref-type="bibr" rid="bibr10-1741826711426090"/><xref ref-type="bibr" rid="bibr11-1741826711426090"/><xref ref-type="bibr" rid="bibr12-1741826711426090"/><xref ref-type="bibr" rid="bibr13-1741826711426090"/><xref ref-type="bibr" rid="bibr14-1741826711426090"/><xref ref-type="bibr" rid="bibr15-1741826711426090"/>–<xref ref-type="bibr" rid="bibr16-1741826711426090">16</xref></sup> However, few studies have examined the effects of smoking cessation on outcome in patients with PAD,<sup><xref ref-type="bibr" rid="bibr29-1741826711426090">29</xref><xref ref-type="bibr" rid="bibr30-1741826711426090"/><xref ref-type="bibr" rid="bibr31-1741826711426090"/><xref ref-type="bibr" rid="bibr32-1741826711426090"/>–<xref ref-type="bibr" rid="bibr33-1741826711426090">33</xref></sup> and most of them had a small sample size and were conducted at a time when medical therapy was not as effective as it is today. Theoretically, similar benefits could be expected in patients presenting with CAD, CVD, or PAD, but our data do not support this hypothesis. Our data confirm that smoking cessation was associated with a substantially lower mortality rate in patients with recent myocardial infarction and a marginally lower mortality rate in patients with CVD, but quitters with PAD had a slightly (non-significantly) higher mortality than persistent smokers. This worse outcome was consistently found in patients presenting at different stages of the disease (Fontaine stages II, III, or IV) and persisted after multivariate adjustment. Thus, our data suggest that the benefit of smoking cessation on survival may be lower in patients with PAD than in those with CAD. Alternatively, we hypothesize that any possible benefit in patients with PAD would need a longer follow-up to be found.</p>
<p>There is increasing evidence suggesting that different arterial risk factors may have a more intense effect on specific arterial beds. It is conceivable that PAD patients represent the end stage of the disease spectrum of atherosclerosis and that interventions that are beneficial at early stages of the disease process may not be beneficial when the disease process reaches the end stage. In autopsy studies, coronary arteries have a high prevalence of plaques, with lipid core plaques being more frequent than fibrous plaques, carotid arteries have more foam cell lesions, and femoral arteries are rich in fibrous plaques, while foam cell lesions are rare.<sup><xref ref-type="bibr" rid="bibr34-1741826711426090">34</xref><xref ref-type="bibr" rid="bibr35-1741826711426090"/>–<xref ref-type="bibr" rid="bibr36-1741826711426090">36</xref></sup> Since cigarette smoking impairs flow-mediated, endothelium-dependent arterial vasodilatation,<sup><xref ref-type="bibr" rid="bibr37-1741826711426090">37</xref></sup> these anatomic differences might partly explain why the effects of smoking cessation on outcome may differ among patients presenting with CAD, CVD, or PAD.</p>
<p>The classic arterial risk factors have different impact in different arterial territories. Cholesterol is particularly important in CAD, hypertension in CVD, and smoking and diabetes in PAD. There is considerable evidence showing that smoking is a potent risk factor for symptomatic PAD, with a consistent dose–response relationship. However, only few studies have examined the effects of smoking cessation on survival in patients with PAD, and most of them had a small sample size, and limited information on confounding factors.<sup><xref ref-type="bibr" rid="bibr37-1741826711426090">37</xref><xref ref-type="bibr" rid="bibr38-1741826711426090"/><xref ref-type="bibr" rid="bibr39-1741826711426090"/><xref ref-type="bibr" rid="bibr40-1741826711426090"/><xref ref-type="bibr" rid="bibr41-1741826711426090"/>–<xref ref-type="bibr" rid="bibr42-1741826711426090">42</xref></sup> They suggest a potential benefit, but since it is conceivable that successful smoking cessation is associated with the control of additional risk factors and preventive medications, the favourable results could result from these confounding factors.</p>
<p>The FRENA registry provides insights into the natural history of artery disease with an unselected patient population, in contrast to the rigorously controlled conditions of randomized clinical studies. It can, therefore, help to identify factors associated with better or worse patient outcomes and provide feedback from real-world clinical situations which may be valuable when designing new randomized clinical studies. Despite our efforts to control any bias from underlying diseases, it is likely that we were unable to eliminate such bias completely. Finally, information on current smoking was self-reported and not validated by any biochemical marker. Self-reported smoking habits, however, have been found to be accurate in studies of different populations.<sup><xref ref-type="bibr" rid="bibr43-1741826711426090">43</xref>,<xref ref-type="bibr" rid="bibr44-1741826711426090">44</xref></sup></p>
<p>Some limitations of our research merit emphasis. First, in our study, quitters were 2 years younger, had fewer comorbidities, and more likely received beta-blockers or angiotensin-converting enzyme inhibitors than persistent smokers. Thus, the different outcome in this study may reflect pre-existing, unrecognized diseases, even after making careful exclusions. Hence, despite our efforts to control any bias from underlying diseases, it is likely that we were unable to eliminate such bias completely. Second, people who quit smoking may have a different lifestyle from people who do quit, and the apparent healthy effects associated with smoking cessation may be mostly due to favourable risk profiles in quitters. Third, the definitions of quitting and persistent smoking relied on self-report, with no biological validation of smoking status. Thus, overreporting of smoking cessation seems possible and the effects of smoking cessation on outcome might have been underestimated. Fourth, patients were recruited from medical centres that provide specialty care for patients with arterial disease. It is possible that this patient population is not representative of all patients with CAD, CVD, or PAD, such as those primarily managed in primary care. Finally, since the events rate for mortality in our series was low (2.7%), the direct comparison between the two groups could be misleading. Unfortunately, randomized controlled trials to assess the influence of smoking cessation in patients with arterial disease are not feasible for several reasons, including ethical considerations, so we have to rely on data from observational studies.</p>
<p>The strengths of the study include its prospective design and the homogeneous study sample, which may have reduced confounding. The study had detailed records of the blood pressure levels, laboratory tests, and use of preventive medications at follow-up visits, enabling us to assess the effects of these important potential confounders. The information on smoking habit at regular intervals during follow-up may have better reflected changes after a cardiovascular event. Moreover, we did not exclude patients with underlying diseases, recent weight loss, or cancer.</p>
<p>In summary, our data confirm that after an arterial event, smoking cessation was associated with a significant decrease in mortality in patients with CAD, a non-significant decrease in those with CVD, and a non-significant increase in those with PAD. The findings in this study complement our knowledge regarding the impact of smoking cessation on outcome in patients with arterial disease, since any differences between current smokers and quitters are of interest.</p>
</sec>
</body>
<back><ack><title>Acknowledgements</title>
<p>We express our gratitude to S &amp; H Medical Science Service for their quality control, logistic and administrative support. We thank Salvador Ortíz, Professor Universidad Autónoma de Madrid and Statistical Advisor S &amp; H Medical Science Service for the statistical analysis of the data presented in this paper.</p>
<p>Members of the FRENA Group: Aguilar E, Àlvarez LR, Arnedo G, Coll R, García-Díaz A, Fuentes E, López-Jiménez L, Monreal M, Mujal A, Pascual MT, Sahuquillo JC, Sánchez Muñoz-Torrero JF, Sanclemente C, Suriñach JM, Toril J.</p></ack>
<sec id="sec11-1741826711426090"><title>Funding</title>
<p>This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.</p>
</sec>
<ref-list><title>References</title>
<ref id="bibr1-1741826711426090"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kawachi</surname><given-names>I</given-names></name><name><surname>Colditz</surname><given-names>GA</given-names></name><name><surname>Stampfer</surname><given-names>MJ</given-names></name><name><surname>Willett</surname><given-names>WC</given-names></name><name><surname>Manson</surname><given-names>JE</given-names></name><name><surname>Rosner</surname><given-names>B</given-names></name><etal/></person-group>. <article-title>Smoking cessation and decreased risk of stroke in women</article-title>. <source>JAMA</source> <year>1993</year>; <volume>269</volume>: <fpage>232</fpage>–<lpage>236</lpage>.</citation></ref>
<ref id="bibr2-1741826711426090"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kawachi</surname><given-names>I</given-names></name><name><surname>Colditz</surname><given-names>GA</given-names></name><name><surname>Stampfer</surname><given-names>MJ</given-names></name><name><surname>Willett</surname><given-names>WC</given-names></name><name><surname>Manson</surname><given-names>JE</given-names></name><name><surname>Rosner</surname><given-names>B</given-names></name><etal/></person-group>. <article-title>Smoking cessation in relation to total mortality rates in women. A prospective cohort study</article-title>. <source>Ann Intern Med</source> <year>1993</year>; <volume>119</volume>: <fpage>992</fpage>–<lpage>1000</lpage>.</citation></ref>
<ref id="bibr3-1741826711426090"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kawachi</surname><given-names>I</given-names></name><name><surname>Colditz</surname><given-names>GA</given-names></name><name><surname>Stampfer</surname><given-names>MJ</given-names></name><name><surname>Willett</surname><given-names>WC</given-names></name><name><surname>Manson</surname><given-names>JE</given-names></name><name><surname>Rosner</surname><given-names>B</given-names></name><etal/></person-group>. <article-title>Smoking cessation and time course of decreased risks of coronary heart disease in middle-aged women</article-title>. <source>Arch Intern Med</source> <year>1994</year>; <volume>154</volume>: <fpage>169</fpage>–<lpage>175</lpage>.</citation></ref>
<ref id="bibr4-1741826711426090"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yusuf</surname><given-names>S</given-names></name><name><surname>Hawken</surname><given-names>S</given-names></name><name><surname>Ounpuu</surname><given-names>S</given-names></name><name><surname>Dans</surname><given-names>T</given-names></name><name><surname>Avezum</surname><given-names>A</given-names></name><name><surname>Lanas</surname><given-names>F</given-names></name><etal/></person-group>. <article-title>Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART Study): a case-control study</article-title>. <source>Lancet</source> <year>2004</year>; <volume>364</volume>: <fpage>937</fpage>–<lpage>952</lpage>.</citation></ref>
<ref id="bibr5-1741826711426090"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pell</surname><given-names>JP</given-names></name><name><surname>Haw</surname><given-names>S</given-names></name><name><surname>Cobbe</surname><given-names>S</given-names></name><name><surname>Newby</surname><given-names>DE</given-names></name><name><surname>Pell</surname><given-names>AC</given-names></name><name><surname>Fischbacher</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Smoke-free legislation and hospitalizations for acute coronary syndrome</article-title>. <source>N Engl J Med</source> <year>2008</year>; <volume>359</volume>: <fpage>482</fpage>–<lpage>491</lpage>.</citation></ref>
<ref id="bibr6-1741826711426090"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>YM</given-names></name><name><surname>Cho</surname><given-names>HJ</given-names></name></person-group>. <article-title>Risk of stroke and myocardial infarction after reduction or cessation of cigarette smoking</article-title>. <source>A cohort study in Korean men. <italic>Stroke</italic></source> <year>2008</year>; <volume>39</volume>: <fpage>2432</fpage>–<lpage>2438</lpage>.</citation></ref>
<ref id="bibr7-1741826711426090"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chow</surname><given-names>CK</given-names></name><name><surname>Lock</surname><given-names>K</given-names></name><name><surname>Teo</surname><given-names>K</given-names></name><name><surname>Subramanian</surname><given-names>S</given-names></name><name><surname>McKee</surname><given-names>M</given-names></name><name><surname>Yusuf</surname><given-names>S</given-names></name></person-group>. <article-title>Environmental and societal influences acting on cardiovascular risk factors and disease at a population level: a review</article-title>. <source>Int J Epidemiol</source> <year>2009</year>; <volume>38</volume>: <fpage>1580</fpage>–<lpage>1594</lpage>.</citation></ref>
<ref id="bibr8-1741826711426090"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Critchley</surname><given-names>J</given-names></name><name><surname>Capewell</surname><given-names>S</given-names></name></person-group>. <article-title>Smoking cessation for the secondary prevention of coronary heart disease</article-title>. <source>Cochrane Database Syst Rev</source> <year>2004</year>; <volume>1</volume>: <fpage>CD003041</fpage>–<lpage>CD003041</lpage>.</citation></ref>
<ref id="bibr9-1741826711426090"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Houston</surname><given-names>TK</given-names></name><name><surname>Allison</surname><given-names>JJ</given-names></name><name><surname>Person</surname><given-names>S</given-names></name><name><surname>Kovac</surname><given-names>S</given-names></name><name><surname>Williams</surname><given-names>OD</given-names></name><name><surname>Kiefe</surname><given-names>CI</given-names></name></person-group>. <article-title>Post-myocardial infarction smoking cessation counselling: associations with immediate and late mortality in older Medicare patients</article-title>. <source>Am J Med</source> <year>2005</year>; <volume>118</volume>: <fpage>269</fpage>–<lpage>275</lpage>.</citation></ref>
<ref id="bibr10-1741826711426090"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Van Spall</surname><given-names>HG</given-names></name><name><surname>Chong</surname><given-names>A</given-names></name><name><surname>Tu</surname><given-names>JV</given-names></name></person-group>. <article-title>Inpatient smoking cessation counselling and all-cause mortality in patients with acute myocardial infarction</article-title>. <source>Am Heart J</source> <year>2007</year>; <volume>154</volume>: <fpage>213</fpage>–<lpage>220</lpage>.</citation></ref>
<ref id="bibr11-1741826711426090"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rallidis</surname><given-names>LS</given-names></name><name><surname>Lekakis</surname><given-names>J</given-names></name><name><surname>Panagiotakos</surname><given-names>D</given-names></name><name><surname>Fountoulaki</surname><given-names>K</given-names></name><name><surname>Komporozos</surname><given-names>C</given-names></name><name><surname>Apostolou</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>Long-term prognostic factors of young patients (&lt;or=35 years) having acute myocardial infarction: the detrimental role of continuation of smoking</article-title>. <source>Eur J Cardiovasc Prev Rehabil</source> <year>2008</year>; <volume>15</volume>: <fpage>567</fpage>–<lpage>571</lpage>.</citation></ref>
<ref id="bibr12-1741826711426090"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chow</surname><given-names>CK</given-names></name><name><surname>Jolly</surname><given-names>S</given-names></name><name><surname>Rao-Melacini</surname><given-names>P</given-names></name><name><surname>Fox</surname><given-names>KAA</given-names></name><name><surname>Anand</surname><given-names>SS</given-names></name><name><surname>Yusuf</surname><given-names>S</given-names></name></person-group>. <article-title>Association of diet, exercise, and smoking modification with risk of early cardiovascular events after acute coronary syndromes</article-title>. <source>Circulation</source> <year>2010</year>; <volume>121</volume>: <fpage>750</fpage>–<lpage>758</lpage>.</citation></ref>
<ref id="bibr13-1741826711426090"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shah</surname><given-names>AM</given-names></name><name><surname>Pfeffer</surname><given-names>MA</given-names></name><name><surname>Hartley</surname><given-names>LH</given-names></name><name><surname>Moyé</surname><given-names>LA</given-names></name><name><surname>Gersh</surname><given-names>BJ</given-names></name><name><surname>Rutherford</surname><given-names>JD</given-names></name><etal/></person-group>. <article-title>Risk of all-cause mortality, recurrent myocardial infarction, and heart failure hospitalization associated with smoking status following myocardial infarction with left ventricular dysfunction</article-title>. <source>Am J Cardiol</source> <year>2010</year>; <volume>106</volume>: <fpage>911</fpage>–<lpage>916</lpage>.</citation></ref>
<ref id="bibr14-1741826711426090"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Frey</surname><given-names>P</given-names></name><name><surname>Waters</surname><given-names>DD</given-names></name><name><surname>Demicco</surname><given-names>DA</given-names></name><name><surname>Breazna</surname><given-names>A</given-names></name><name><surname>Samuels</surname><given-names>L</given-names></name><name><surname>Pipe</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Impact of smoking on cardiovascular events in patients with coronary disease receiving contemporary medical therapy (from the Treating to new targets (TNT) and the Incremental decrease in end points through aggressive lipid lowering (IDEAL) trials)</article-title>. <source>Am J Cardiol</source> <year>2011</year>; <volume>107</volume>: <fpage>145</fpage>–<lpage>150</lpage>.</citation></ref>
<ref id="bibr15-1741826711426090"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shah</surname><given-names>RS</given-names></name><name><surname>Cole</surname><given-names>JW</given-names></name></person-group>. <article-title>Smoking and stroke: the more you smoke the more you stroke</article-title>. <source>Expert Rev Cardiovasc Ther</source> <year>2010</year>; <volume>8</volume>: <fpage>917</fpage>–<lpage>932</lpage>.</citation></ref>
<ref id="bibr16-1741826711426090"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ives</surname><given-names>SP</given-names></name><name><surname>Heuschmann</surname><given-names>PU</given-names></name><name><surname>Wolfe</surname><given-names>CD</given-names></name><name><surname>Redfern</surname><given-names>J</given-names></name></person-group>. <article-title>Patterns of smoking cessation in the first 3 years after stroke: the South London Stroke Register</article-title>. <source>Eur J Cardiovasc Prev Rehabil</source> <year>2008</year>; <volume>15</volume>: <fpage>329</fpage>–<lpage>335</lpage>.</citation></ref>
<ref id="bibr17-1741826711426090"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Adams</surname><given-names>RJ</given-names></name><name><surname>Albers</surname><given-names>G</given-names></name><name><surname>Alberts</surname><given-names>MJ</given-names></name><name><surname>Benavente</surname><given-names>O</given-names></name><name><surname>Furie</surname><given-names>K</given-names></name><name><surname>Goldstein</surname><given-names>LB</given-names></name><etal/></person-group>. <article-title>American Heart Association, American Stroke Association. Update to the AHA/ASA recommendations for the prevention of stroke in patients with stroke and transient ischemic attack</article-title>. <source>Stroke</source> <year>2008</year>; <volume>39</volume>: <fpage>1647</fpage>–<lpage>1652</lpage>.</citation></ref>
<ref id="bibr18-1741826711426090"><label>18</label><citation citation-type="journal"><collab>European Stroke Organisation (ESO) Executive Committee and ESO Writing Committee</collab>. <article-title>Guidelines for management of ischaemic stroke and transient ischaemic attack 2008</article-title>. <source>Cerebrovasc Dis</source> <year>2008</year>; <volume>25</volume>: <fpage>457</fpage>–<lpage>507</lpage>.</citation></ref>
<ref id="bibr19-1741826711426090"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Norgren</surname><given-names>L</given-names></name><name><surname>Hiatt</surname><given-names>WR</given-names></name><name><surname>Dormandy</surname><given-names>JA</given-names></name><name><surname>Nehler</surname><given-names>MR</given-names></name><name><surname>Harris</surname><given-names>KA</given-names></name><name><surname>Fowkes</surname><given-names>FGR</given-names></name></person-group>. <collab>on behalf of the TASC II Working Group</collab>. <article-title>Inter-Society consensus for the management of peripheral arterial disease (TASC II)</article-title>. <source>Eur J Vasc Endovasc Surg</source> <year>2007</year>; <volume>33</volume>: <fpage>S1</fpage>–<lpage>S70</lpage>.</citation></ref>
<ref id="bibr20-1741826711426090"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hankey</surname><given-names>GJ</given-names></name><name><surname>Norman</surname><given-names>PE</given-names></name><name><surname>Eikelboom</surname><given-names>JW</given-names></name></person-group>. <article-title>Medical treatment of peripheral arterial disease</article-title>. <source>JAMA</source> <year>2006</year>; <volume>295</volume>: <fpage>547</fpage>–<lpage>553</lpage>.</citation></ref>
<ref id="bibr21-1741826711426090"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Barba</surname><given-names>R</given-names></name><name><surname>Bisbe</surname><given-names>J</given-names></name><name><surname>Pedrajas</surname><given-names>JN</given-names></name><name><surname>Toril</surname><given-names>J</given-names></name><name><surname>Monte</surname><given-names>R</given-names></name><name><surname>Muñoz-Torrero</surname><given-names>JF</given-names></name><etal/></person-group>. <article-title>and the FRENA Investigators. Body mass index and outcome in patients with coronary, cerebrovascular, or peripheral artery disease: Findings from the FRENA Registry</article-title>. <source>Eur J Cardiovasc Prev Rehabil</source> <year>2009</year>; <volume>17</volume>: <fpage>456</fpage>–<lpage>463</lpage>.</citation></ref>
<ref id="bibr22-1741826711426090"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Suriñach</surname><given-names>JM</given-names></name><name><surname>Alvarez</surname><given-names>LR</given-names></name><name><surname>Coll</surname><given-names>R</given-names></name><name><surname>Carmona</surname><given-names>JA</given-names></name><name><surname>Sanclemente</surname><given-names>C</given-names></name><name><surname>Aguilar</surname><given-names>E</given-names></name><etal/></person-group>. <article-title>Differences in cardiovascular mortality in smokers, past-smokers and non-smokers. Findings from the FRENA Registry</article-title>. <source>Eur J Intern Med</source> <year>2009</year>; <volume>20</volume>: <fpage>522</fpage>–<lpage>526</lpage>.</citation></ref>
<ref id="bibr23-1741826711426090"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Camafort</surname><given-names>M</given-names></name><name><surname>Alvarez-Rodríguez</surname><given-names>LR</given-names></name><name><surname>Muñoz-Torrero</surname><given-names>JF</given-names></name><name><surname>Sahuquillo</surname><given-names>JC</given-names></name><name><surname>López-Jiménez</surname><given-names>L</given-names></name><name><surname>Coll</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Glucose control and outcome in patients with stable diabetes and previous coronary, cerebrovascular or peripheral artery disease. Findings from the FRENA Registry</article-title>. <source>Diabet Med</source> <year>2011</year>; <volume>28</volume>: <fpage>73</fpage>–<lpage>80</lpage>.</citation></ref>
<ref id="bibr24-1741826711426090"><label>24</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Muñoz-Torrero</surname><given-names>JF</given-names></name><name><surname>Escudero</surname><given-names>D</given-names></name><name><surname>Suárez</surname><given-names>C</given-names></name><name><surname>Sanclemente</surname><given-names>C</given-names></name><name><surname>Pascual</surname><given-names>MT</given-names></name><name><surname>Zamorano</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Concomitant use of proton-pump inhibitors and clopidogrel in patients with coronary, cerebrovascular, or peripheral artery disease in the FRENA Registry</article-title>. <source>J Cardiovasc Pharmacol</source> <year>2011</year>; <volume>57</volume>: <fpage>13</fpage>–<lpage>19</lpage>.</citation></ref>
<ref id="bibr25-1741826711426090"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>García-Díaz</surname><given-names>AM</given-names></name><name><surname>Marchena</surname><given-names>PJ</given-names></name><name><surname>Toril</surname><given-names>J</given-names></name><name><surname>Arnedo</surname><given-names>G</given-names></name><name><surname>Sánchez Muñoz-Torrero</surname><given-names>JF</given-names></name><name><surname>Yeste</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Alcohol consumption and outcome in stable outpatients with peripheral artery disease</article-title>. <source>J Vasc Surg</source> <year>2011</year>. <comment>[Epub ahead of print]</comment>.</citation></ref>
<ref id="bibr26-1741826711426090"><label>26</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dormandy</surname><given-names>JA</given-names></name><name><surname>Rutherford</surname><given-names>B</given-names></name></person-group>. <article-title>Management of peripheral arterial disease (PAD) TASC Working Group. Trans Atlantic Inter-Society Consensus (TASC)</article-title>. <source>J Vasc Surg</source> <year>2000</year>; <volume>31</volume>: <fpage>S1</fpage>–<lpage>S96</lpage>.</citation></ref>
<ref id="bibr27-1741826711426090"><label>27</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cockcroft</surname><given-names>DW</given-names></name><name><surname>Gault</surname><given-names>MH</given-names></name></person-group>. <article-title>Prediction of creatinine clearance from serum creatinine</article-title>. <source>Nephron</source> <year>1976</year>; <volume>16</volume>: <fpage>31</fpage>–<lpage>41</lpage>.</citation></ref>
<ref id="bibr28-1741826711426090"><label>28</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Martin</surname><given-names>DO</given-names></name><name><surname>Austin</surname><given-names>H</given-names></name></person-group>. <article-title>Exact estimates for a rate ratio</article-title>. <source>Epidemiology</source> <year>1996</year>; <volume>7</volume>: <fpage>29</fpage>–<lpage>33</lpage>.</citation></ref>
<ref id="bibr29-1741826711426090"><label>29</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hughson</surname><given-names>WG</given-names></name><name><surname>Mann</surname><given-names>JI</given-names></name><name><surname>Tibbs</surname><given-names>DJ</given-names></name><name><surname>Woods</surname><given-names>HF</given-names></name><name><surname>Walton</surname><given-names>I</given-names></name></person-group>. <article-title>Intermittent claudication: factors determining outcome</article-title>. <source>BMJ</source> <year>1978</year>; <volume>1</volume>: <fpage>1377</fpage>–<lpage>1379</lpage>.</citation></ref>
<ref id="bibr30-1741826711426090"><label>30</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Quick</surname><given-names>CRG</given-names></name><name><surname>Cotton</surname><given-names>LT</given-names></name></person-group>. <article-title>The measured effect of stopping smoking on intermittent claudication</article-title>. <source>Br J Surg</source> <year>1982</year>; <volume>69</volume>(<issue>suppl</issue>): <fpage>S24</fpage>–<lpage>S26</lpage>.</citation></ref>
<ref id="bibr31-1741826711426090"><label>31</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jonason</surname><given-names>T</given-names></name><name><surname>Bergstrom</surname><given-names>R</given-names></name></person-group>. <article-title>Cessation of smoking in patients with intermittent claudication</article-title>. <source>Acta Med Scand</source> <year>1987</year>; <volume>221</volume>: <fpage>253</fpage>–<lpage>260</lpage>.</citation></ref>
<ref id="bibr32-1741826711426090"><label>32</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>I</given-names></name><name><surname>Franks</surname><given-names>PJ</given-names></name><name><surname>Greenhalgh</surname><given-names>RM</given-names></name><name><surname>Poulter</surname><given-names>NR</given-names></name><name><surname>Powell</surname><given-names>JT</given-names></name></person-group>. <article-title>The influence of smoking cessation and hypertriglyceridaemia on the progression of peripheral arterial disease and the onset of critical ischemia</article-title>. <source>Eur J Endovasc Surg</source> <year>1996</year>; <volume>11</volume>: <fpage>402</fpage>–<lpage>408</lpage>.</citation></ref>
<ref id="bibr33-1741826711426090"><label>33</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Conen</surname><given-names>D</given-names></name><name><surname>Everett</surname><given-names>BM</given-names></name><name><surname>Kurth</surname><given-names>T</given-names></name><name><surname>Creager</surname><given-names>MA</given-names></name><name><surname>Buring</surname><given-names>JE</given-names></name><name><surname>Ridker</surname><given-names>PM</given-names></name><etal/></person-group>. <article-title>Smoking, smoking status, and risk for symptomatic peripheral artery disease in women. A cohort study</article-title>. <source>Ann Intern Med</source> <year>2011</year>; <volume>154</volume>: <fpage>719</fpage>–<lpage>726</lpage>.</citation></ref>
<ref id="bibr34-1741826711426090"><label>34</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Paraskevas</surname><given-names>KI</given-names></name><name><surname>Bessias</surname><given-names>N</given-names></name><name><surname>Papas</surname><given-names>TT</given-names></name><name><surname>Gekas</surname><given-names>CH</given-names></name><name><surname>Andrikopoulos</surname><given-names>V</given-names></name><name><surname>Mikhailidis</surname><given-names>DP</given-names></name></person-group>. <article-title>Do different vascular risk factors affect all arteries equally?</article-title> <source>Angiology</source> <year>2008</year>; <volume>59</volume>: <fpage>397</fpage>–<lpage>401</lpage>.</citation></ref>
<ref id="bibr35-1741826711426090"><label>35</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dalager</surname><given-names>S</given-names></name><name><surname>Paaske</surname><given-names>WP</given-names></name><name><surname>Kristensen</surname><given-names>IB</given-names></name><name><surname>Laurberg</surname><given-names>JM</given-names></name><name><surname>Falk</surname><given-names>E</given-names></name></person-group>. <article-title>Artery-related differences in atherosclerosis expression. Implications for atherogenesis and dynamics in intima-media thickness</article-title>. <source>Stroke</source> <year>2007</year>; <volume>38</volume>: <fpage>2698</fpage>–<lpage>2705</lpage>.</citation></ref>
<ref id="bibr36-1741826711426090"><label>36</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Slevin</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Font</surname><given-names>MA</given-names></name><name><surname>Luque</surname><given-names>A</given-names></name><name><surname>Juan-Babot</surname><given-names>O</given-names></name><name><surname>Gaffney</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Atherothrombosis and plaque heterology: different location or a unique disease?</article-title> <source>Pathobiology</source> <year>2008</year>; <volume>75</volume>: <fpage>209</fpage>–<lpage>225</lpage>.</citation></ref>
<ref id="bibr37-1741826711426090"><label>37</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Willigendael</surname><given-names>EM</given-names></name><name><surname>Teijink</surname><given-names>JA</given-names></name><name><surname>Bartelink</surname><given-names>ML</given-names></name><name><surname>Kuiken</surname><given-names>BW</given-names></name><name><surname>Boiten</surname><given-names>J</given-names></name><name><surname>Moll</surname><given-names>FL</given-names></name><etal/></person-group>. <article-title>Influence of smoking on incidence and prevalence of peripheral arterial disease</article-title>. <source>J Vasc Surg</source> <year>2004</year>; <volume>40</volume>: <fpage>1158</fpage>–<lpage>1165</lpage>.</citation></ref>
<ref id="bibr38-1741826711426090"><label>38</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Faulkner</surname><given-names>KW</given-names></name><name><surname>Hosue</surname><given-names>AK</given-names></name><name><surname>Castleden</surname><given-names>WM</given-names></name></person-group>. <article-title>The effect of cessation of smoking on the accumulative survival rates of patients with symptomatic peripheral vascular disease</article-title>. <source>Med J Aust</source> <year>1983</year>; <volume>1</volume>: <fpage>217</fpage>–<lpage>219</lpage>.</citation></ref>
<ref id="bibr39-1741826711426090"><label>39</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lassila</surname><given-names>R</given-names></name><name><surname>Lepantalo</surname><given-names>M</given-names></name></person-group>. <article-title>Cigarette smoking and the outcome after lower limb arterial surgery</article-title>. <source>Acta Chir Scand</source> <year>1988</year>; <volume>154</volume>: <fpage>635</fpage>–<lpage>640</lpage>.</citation></ref>
<ref id="bibr40-1741826711426090"><label>40</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Godtfredsen</surname><given-names>NS</given-names></name><name><surname>Holst</surname><given-names>C</given-names></name><name><surname>Prescott</surname><given-names>E</given-names></name><name><surname>Vestbo</surname><given-names>J</given-names></name><name><surname>Osler</surname><given-names>M</given-names></name></person-group>. <article-title>Smoking reduction, smoking cessation, and mortality: a 16-year follow-up of 19732 men and women from the Copenhagen Centre for Prospective Population Studies</article-title>. <source>Am J Epidemiol</source> <year>2002</year>; <volume>156</volume>: <fpage>994</fpage>–<lpage>1001</lpage>.</citation></ref>
<ref id="bibr41-1741826711426090"><label>41</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jonason</surname><given-names>T</given-names></name><name><surname>Bergstrom</surname><given-names>R</given-names></name></person-group>. <article-title>Cessation of smoking in patients with intermittent claudication. Effects on the risk of peripheral vascular complications, myocardial infarction and mortality</article-title>. <source>Acta Med Scand</source> <year>1987</year>; <volume>221</volume>: <fpage>253</fpage>–<lpage>260</lpage>.</citation></ref>
<ref id="bibr42-1741826711426090"><label>42</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Girolami</surname><given-names>B</given-names></name><name><surname>Bernardi</surname><given-names>E</given-names></name><name><surname>Prins</surname><given-names>MH</given-names></name><name><surname>ten Cate</surname><given-names>JW</given-names></name><name><surname>Hettiarachchi</surname><given-names>R</given-names></name><name><surname>Prandoni</surname><given-names>P</given-names></name><etal/></person-group>. <article-title>Treatment of intermittent claudication with physical training, smoking cessation, pentoxifylline, or nafronyl. A meta-analysis</article-title>. <source>Arch Intern Med</source> <year>1999</year>; <volume>159</volume>: <fpage>337</fpage>–<lpage>345</lpage>.</citation></ref>
<ref id="bibr43-1741826711426090"><label>43</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Patrick</surname><given-names>DL</given-names></name><name><surname>Cheadle</surname><given-names>A</given-names></name><name><surname>Thrompson</surname><given-names>DC</given-names></name><name><surname>Diehr</surname><given-names>P</given-names></name><name><surname>Koepsell</surname><given-names>T</given-names></name><name><surname>Kinne</surname><given-names>S</given-names></name></person-group>. <article-title>The validity of self-reported smoking: a review and meta-analysis</article-title>. <source>Am J Public Health</source> <year>1994</year>; <volume>84</volume>: <fpage>1086</fpage>–<lpage>1093</lpage>.</citation></ref>
<ref id="bibr44-1741826711426090"><label>44</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Attebring</surname><given-names>MF</given-names></name><name><surname>Herlitz</surname><given-names>J</given-names></name><name><surname>Berndt</surname><given-names>A-K</given-names></name><name><surname>Karlsson</surname><given-names>T</given-names></name><name><surname>Hjalmarson</surname><given-names>A</given-names></name></person-group>. <article-title>Are patients truthful about their smoking habits? A validation of self-report about smoking cessation with biochemical markers of smoking activity amongst patients with ischaemic heart disease</article-title>. <source>J Intern Med</source> <year>2001</year>; <volume>249</volume>: <fpage>145</fpage>–<lpage>151</lpage>.</citation></ref>
</ref-list>
</back>
</article>